Histology, classification and natural history of cervical intraepithelial neoplasia (CIN)

CME Journal of Gynecologic Oncology

Volumn 14, Issue 1, 2009, Pages 4-21

  Syrjänen, Kari J ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

CIN; Classifications; Follow up; Markers; Morphology; Natural history; Prognosis

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 3; NUCLEOSIDE DIPHOSPHATE KINASE A; PROTEIN LR 67; PROTEIN PCNA; PROTEIN TOPO 2 ALPHA; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN C; VIRUS DNA;

BASAL CELL; BIOPSY; CANCER CLASSIFICATION; CELL DIFFERENTIATION; COLPOSCOPY; CYTOGENETICS; EPITHELIUM CELL; ETHICS; FOLLOW UP; HISTOLOGY; HOST CELL; HUMAN; MITOSIS; PAPANICOLAOU TEST; PROGNOSIS; REVIEW; RISK FACTOR; UTERINE CERVIX CARCINOMA IN SITU; VAGINA CYTOLOGY; WART VIRUS; WOMEN'S HEALTH;

EID: 70349776229     PISSN: 12199087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Östor AG. Natural history of cervical intraepithelial neoplasia - a critical review. Int J Gynecol Pathol 1993;12:186-192.
2. Syrjänen, K. Natural history of cervical HPV infections and CIN. Chapter 6. In: Syrjänen, K, Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 142-166.
3. IARC Monographs on the evaluation of carcinogenic risks to humans. Volume 64. Papillomavirusus. IARC, Lyon 1995; pp. 1-409.
4. Rubin SC, Hoskins WJ. (eds). Cervical Cancer and Preinvasive Neoplasia. Chapter 6. Lippincott-Raven Publications, Philadelphia 1996; pp. 77-92.
5. Koss LG, Stewart FW, Foote FW, Jordan MJ, Bader GM, Day E. Some histological aspects of behavior of epidermoid carcinoma in situ and related lesions of the uterine cervix. Cancer 1963; 16:1160-1211.
6. Fox CH. Biologic behavior of dysplasia and carxinoma in situ. Am J Obstet Gynecol 1967;99:960-974.
7. Richart RM. Cervical intraepithelial neoplasia. Pathol Annu 1973;8:301-328.
8. Syrjänen KJ. Natural history of HPV infections: Recent developments. In: Monsonego J. (Ed). 5th International Multidisciplinary Congress EUROGIN 2003. Monduzi Editore, Milano 2003, pp.1-9.
9. Costa S, Syrjänen K. Le lesioni squamose preinvasive: I precursori del carcinoma cervicale. Chapter 8. In: Costa S, Syrjänen, K. (eds). Gestione delle Pazienti con PAP Test Anormale. Athena Audiovisuals, Modena, pp. 225-254, 2005.
10. Syrjänen KJ. Morphological diagnosis. In: Monsonego J. (ed). Emerging Issues of HPV Infetions: From Science to Practice. Basel, Karger 2006; pp. 157-164.
11. Syrjänen KJ. Evolución natural de las infecciones por papillomavirus humano. In: Tatti, S: (Ed). Colposcopia y Patologías del Tracto Genital Inferior. Editorial Médica Panamericana, Buenos Aires, 2008; pp. 64-71.
12. Hellberg D, Nilsson S, Gad A, Hongxiu J, Fuju C, Syrjänen S, Syrjänen K. Behavior of cervical intraepithelial neoplasia (CIN) associated with various human papillomavirus (HPV) types. Arch Gynecol Obstet 1993;252:119-128. (Pubitemid 23107061)
13. Hellberg D, Nilsson S, Valentin J. Positive cervical smear with subsequent normal colposcopy and histology - frequency of CIN in a long-term follow-up. Gynecol Oncol 1994;53:148-151. (Pubitemid 24177036)
14. Syrjänen KJ. Genital Human papillomavirus (HPV) infections and their associations with squamous cell cancer: Reapprisal of the morphologic, epidemiologic and DNA data. In: Progress in Surgical Pathology. (Eds) C.M. Fenoglio-Preiser, M. Wolff and F. Rilke. Field & Wood. 1992; XII: pp. 217-240.
15. Franco EL. Cancer causes revisited: human papillomavirus and cervical neoplasia. J Nat Cancer Inst 1995;87:779-780.
16. Franco EL. Epidemiology of anogenital warts and cancer. Obstet Gynecol Clin North Am 1996;23:597-623.
17. Franco EL. Understanding the epidemiology of genital infection with oncogenic and nononcogenic human papillomaviruses: A promising lead for primary prevention of cervical cancer. Cancer Epidem Biomarker Prev 1997;6:759-761.
18. Duffy SW, Rohan TE, McLaughlin JR. Design and analysis considerations in a cohort study involving repeated measurement of both exposure and outcome: the association between genital papillomavirus infection and risk of cervical intraepithelial neoplasia. Stat Med 1994;13:379-390.
19. Syrjänen KJ. Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated HPV. Eur J Obstet Gynecol Reprod Biol 1996;65:45-53.
20. Syrjänen KJ. Natural history of genital Human papillomavirus infections. In: Lacey C. (ed). Papillomavirus Reviews. Current Research on Papillomaviruses. Leeds Medical Information, Leeds University Press, Leeds, 1996; pp. 189-206.
21. Syrjänen KJ. Natural history of cervical cancer and its implications on screening policy. In: Monsonego J. (ed.). Proceedings of the 3rd International Congress on Lower Genital Tract Infections and Neoplasia. Papillomavirus in Human Pathology, Paris, France, March 24-27, 1997; pp. 123-140.
22. Schottländer J, Kemauner F. Zur Kenntnis des Uteruskarzinoms: Monographische Studie über Morphologie, Entwicklung, Wachstum. Beiträgen zur Klinik der Erkrankung, S. Karger, Berlin. 1912; pp. 1-90.
23. Riotton G, Christopherson WM, Lunt R. (eds). International Histological Classification of Tumors. No.8. Cytology of the Female Genital Tract. World Health Organization, Geneva. 1973.
24. Patten SF, Jr. Dysplasia of the uterine cervix. In: Lewis GC Jr, Wentz WB, Jaffe RM. (eds.). New Concepts in Gynecological Oncology. FA Davis, Philadelphia 1966; pp. 33-44.
25. Richart RM. The patient with an abnormal smear: Screening techniques and management. N Engl J Med 1980;302:332-334.
26. Richart RM. Causes and management of cervical intraepithelial neoplasia. Cancer 1987;60(8 Suppl):1951-1959 (Pubitemid 17145914)
27. Syrjänen KJ. Human papillomavirus (HPV) infections of the female genital tract and their associations with intraepithelial neoplasia and squamous cell carcinoma. Pathol Annu 1986;21: 53-89.
28. Richart RM. A modified terminology for cervical intraepithelial neoplasia. Obstet Gynecol 1990;75:131-133.
29. National Cancer Institute Workshop. The 1988 Bethesda system for reporting cervical/ vaginal cytological diagnoses. JAMA 1989;262:931-934.
30. Kurman RJ, Malkasian GD, Sedlis A, Solomon D. From Papanicolaou to Bethesda: The rationale for a new clinical cytologic classification. Obstet Gynecol 1991;77:779-782.
31. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-2119.
32. Syrjänen K, Kataja V, Yliskoski M, Chang F, Syrjänen S, Saarikoski S. Natural history of cervical HPV lesions does not substantiate the biologic relevance of the Bethesda system. Obstet Gynecol 1992;79:675-682.
33. Spriggs AI. Natural history of cervical dysplasia. Clin Obstet Gynaecol 1981; 8:65-76.
34. Nasiell K, Nasiell M, Vaclavinkova U. Behavior of moderate cervical dysplasia during long term follow up. Obstet Gynecol 1983;61:609-614.
35. Nasiell K, Roger V, Nasiell M. Behavior of mild cervical dysplasia during long term follow-up. Obstet Gynecol 1986;67:665-669. (Pubitemid 16111924)
36. Franco EL. Viral etiology of cervical cancer. A critique of the evidence. Rev Infect Dis 1991;13:1195-1206.
37. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988;10:122-163. (Pubitemid 18262843)
38. Munoz N, Bosch X, Kaldor JM. Does human papillomavirus cause cervical cancer? The state of the epidemiological evidence. Br J Cancer 1988;57:1-5. (Pubitemid 18067096)
39. Munoz N, Bosch FX, Jensen OM. (eds.). Human papillomavirus and cervical cancer. IARC Scientific Publications 1990; No.94. pp. 1-151.
40. Munoz N, Bosch FX, Shah K, Meheus A. (eds.). The epidemiology of human papillomavirus and cervical cancer. IARC Scientific Publications 1992; No.119. pp. 1-288.
41. Bibbo M, Dytch HE, Alenghat E, Bartels PH, Wied GL. DNA ploidy profiles as prognostic indicators in CIN lesions. Am J Clin Pathol 1989;92:261-265. (Pubitemid 19228922)
42. Stern E, Neely PM. Dysplasia of the uterine cervix incidence of regression reccurrence and cancer. Cancer 1964;17:508-512.
43. Byrne MA, Parry GC, Morse A, Taylor Robinson D, Malcolm AD, Coleman DV. A prospective study of human papillomavirus infection of the cervix. Cytopathology 1990; 1:329-337.
44. Chua KL, Wiklund F, Lenner P, Angstrom T, Hallmans G, Bergman F, Sapp M, Schiller J, Wadell G, Hjerpe A, et al. A prospective study on the risk of cervical intraepithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears. Int J Cancer 1996;68:54-59. (Pubitemid 26354579)
45. Bauer HM, Hildesheim A, Schiffman MH, Glass AG, Rush BB, Scott DR, Cadell DM, Kurman RJ, Manos MM. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sex Transm Dis 1993;20:274-278. (Pubitemid 23286957)
46. Hildesheim A, Gravitt P, Schiffman MH, et al. Determinants of genital human papillomavirus infection in low-income women in washington, DC. Sex Transm Dis 1993;20:279-285. (Pubitemid 23286958)
47. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, Lawler P, Sherman ME, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-240. (Pubitemid 24045578)
48. Rozendaal L, Walboomers JM, van-der-Linden JC, Voorhorst FJ, Kenemans P, Helmerhorst TJ, van-Ballegooijen M, Meijer CJ. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 1996;68:766-769.
49. Veress G, Csiky-Meszaros T, Konya J, Czegledy J, Gergely L. Follow-up of human papillomavirus (HPV) DNA and local anti-HPV antibodies in cytologically normal pregnant women. Med Microbiol Immunol Berl 1996;185:139-144. (Pubitemid 27007706)
50. deGruijl TD, Bontkes HJ, Walboomers JM, Stukart MJ, Robbesom AA, von-Blomberg-van-der-Flier BM, Herbrink P, Remmink AJ, Verheijen RH, Helmerhorst TJ. Analysis of IgG reactivity against Human Papillomavirus type-16 E7 in patients with cervical intraepithelial neoplasia indicates an association with clearance of viral infection: results of a prospective study. Int J Cancer 1996;68:731-738.
51. Varga A. The relationship of cervical dysplasia to in situ and invasive carcinoma of the cervix. Am J Obstet Gynecol 1966;95:759-762.
52. Richart RM, Barron BA. A follow up study of patients with cervical dysplasia. Am J Obstet Gynecol 1969;105:386-393.
53. Mitchell H, Drake M, Medley G. Prospective evaluation of risk of cervical cancer after cytological evidence of human papilloma virus infection. Lancet 1986;i:573-575. (Pubitemid 16138381)
54. Montz FJ, Monk BJ, Fowler JC, Nguyen L. Natural history of the minimally abnormal Papanicolaou smear. Obstet Gynecol 1992;80:385-388.
55. Quitllet FA, Morta MC, Canas A, Castellanos E, Carreras R. Cytologic atypia. Clinical significance and follow-up recommendations. Acta Cytol 1997;41:504-506.
56. Chang AR. Carcinoma in situ of the cervix and its malignant potential. A lession from New Zealand. Cytopathol 1990;1:321-328.
57. Mitchell MF, Hittelman WN, Hong WK, Lotan R, Schottenfeld D. The natural history of cervical intraepithelial neoplasia: an argument for intermediate endpoint biomarkers. Cancer Epidemiol Biomarkers Prev 1994;3:619-626. (Pubitemid 24314452)
58. Burghardt E, Östör AG. Colposcopy, cervical pathology. Textbook and atlas. 2nd ed. Georg Thieme, New York, 1991; pp. 1-541.
59. Syrjänen K, Väyrynen M, Saarikoski S, Mäntyjärvi R, Parkkinen S, Hippeläinen M, Castren O. Natural history of cervical Human papillomavirus (HPV) infections based on prospective follow-up. Brit J Obstet Gynaecol 1985;92:1086-1092. (Pubitemid 16249338)
60. Syrjänen K, de Villiers E-M, Väyrynen M, Mäntyjärvi R, Parkkinen S, Castren O. Cervical papilomavirus infection progressing to invasive cancer in less than three years. Lancet, 1985;i:510-511.
61. Kataja V, Syrjänen K, Mäntyjärvi R, Väyrynen M, Syrjänen S, Saarikoski S, Parkkinen S, Yliskoski M, Salonen JT, Castren O. Prospective follow-up of cervical HPV infections: Life-Table analysis of histopathological, cytological and colposcopic data. Eur J Epidemiol 1989;5:1-7. (Pubitemid 19085675)
62. Kataja V, Syrjänen K, Syrjänen S, Mäntyjärvi R, Yliskoski M, Saarikoski S, Mäntyjärvi R, Salonen JT. Prospective follow-up of genital HPV infections: Survival analysis of the HPV typing data. Eur J Epidemiol 1990;6:9-14. (Pubitemid 20132541)
63. Kataja V, Syrjänen K, Syrjänen S, Mäntyjärvi R, Yliskoski M, Saarikoski S, Salonen JT. Prognostic factors in cervical human papillomavirus (HPV) infections. Sex Transm Dis 1992;19:154-160.
64. Kataja V, Syrjänen S, Yliskoski M, Hippeläinen M, Väyrynen M, Saarikoski S, Mäntyjärvi R, Jokela V, Salonen JT, Syrjänen K. Risk factors associated with cervical human papillomavirus (HPV) infections: A case-control study. Am J Epidemiol 1993;138:735-745. (Pubitemid 23339016)
65. Hardin J, Hilbe JM. Generalized estimating equations. (Eds). Boca Raton, FL: Chapman & Hall, 2003; pp. 1-222.
66. Alonzo TA. Verification bias-corrected estimators of the relative true and false positive rates of two binary screening tests. Stat Med 2005;24:403-417.
67. Reichenheim ME, Ponce de Leon A. Estimation of sensitivity and specificity arising from validity studies with incomplete designs. Stata J 2002;2:267-279.
68. Martinez EZ, Louzada-Neto F, Derchain SFM, Achar JA, Gontijo RC, Sarian LOZ, Syrjänen KJ. Bayesian estimation of performance measures of cervical cancer screening tests in the presence of covariates and absence of a gold standard. Cancer Informat. 2008;4:3-46.
69. Richardson AC, Lyon JB. The effect of condom use on squamous cell cervical intraepithelial neoplasia. Am J Obstet Gynecol 1981;140:909-913.
70. Glatthaar E. Studien uber die Morphogenese des Plattenepithelkarzinoms der Portio vaginalis uteri. Karger AG, Basel, 1950.
71. Younge PA. The conservative treatment of carcinoma in situ of the cervix. Proceedings of the Third National Cancer Conference, Detroit, 1957; pp. 682-692.
72. Fu YS, Reagan YW, Richart RM.Definition of precursors. Gynecol Oncol 1981;12: S220-231.
73. McIndoe WA, McLean MR, Jones RW, Mullins P. The invasive potential of carcinoma in situ of the cervix. Obstet Gynecol 1984;64:451-458. (Pubitemid 14013986)
74. Bibbo M, Dytch HE, Alenghat E, Bartels PH, Wied GL. DNA ploidy profiles as prognostic indicators in CIN lesions. Am J Clin Pathol 1989;92:261-265. (Pubitemid 19228922)
75. Noda K. Follow-up study of cervical dysplasia. Nipp Sank GAk Zas 1966;18:875-877.
76. von Piringer-Kuchinka A, Martin I, Kofler E. Zur Frage der biologischen Wertigkeit und Therapie des sogenannten präinvasiven Portiokarzinoms. Geburtsh Frauenheilk 1956;16:971-992.
77. Fox H, Buckley CH (Eds). Histopathology Reporting in Cervical Screening. NHSCSP Publications No 10, Sheffield 1999; pp. 1-56.
78. Fox H, Wells M. (eds.). Haines & Taylor Obstetrical and Gynaecological Pathology, 5th Ed., Churchill Livinsgtone, Edinburgh 2003; Vol 1: pp. 297-338.
79. Syrjänen KJ. Management of abnormal PAP smears (MAPS): Implications of terminology used in cytopathology. J Lower Genital Tract Dis 2000;4:217-223.
80. Syrjänen K. Early detection of CIN and HPV: Prevention of cervical cancer. Chapter 7. In: Syrjänen K, Syrjänen S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000: pp. 167-188.
81. Syrjänen, K.J. Immunohistochemistry in assessment of molecular pathogenesis of cervical carcinogenesis. Eur J Gynaecol Oncol 2005;26:5-19.
82. von Knebel-Döberitz M, Syrjänen K. Molecular markers. How to apply in practice. Gynecol Oncol 2006;103:18-20.
83. Branca M, Costa S, Mariani L, Piccione E, Sesti F, Agarossi A, di Carlo A, Galati M, Ciotti M, Paba P, Benedetto A, Giorgi C, Criscuolo A, Valieri M, Favalli C, Santini D, Alderisio M, De Nuzzo M, di Bonito L, Syrjänen K. Assessment of risk factors and Human papillomavirus (HPV) related pathogenetic mechanisms of CIN in HIV-positive and HIV-negative women. Study design and baseline data of the HPVPathogenISS study. Eur J Gynaecol Oncol 2004;25: 689-698. (Pubitemid 39576945)
84. Branca M, Ciotti M, Giorgi C, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Syrjänen S, Favalli C, Syrjänen K. Predicting high-risk human papillomavirus (HPV) infection, progression of cervical intraepithelial neoplasia (CIN) and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modelling. Int J Gynecol Pathol 2008;27:265-273.
85. Branca M, Ciotti M, Santini D, Di Bonito L, Giorgi C, Benedetto A et al. p16INK4A expression is related to grade of CIN and high-risk Human papillomavirus but does not predict virus clearance after conization or disease outcome. Int J Gynecol Pathol 2004;23:354-365. (Pubitemid 39299024)
86. Branca M, Ciotti M, Santini D, Bonito LD, Benedetto A, Giorgi C, Paba P, Favalli C, Costa S, Agarossi A, Alderisio M, Syrjanen K. Activation of the ERK/MAP kinase pathway in cervical intraepithelial neoplasia is related to grade of the lesion but not to high-risk human papillomavirus, virus clearance, or prognosis in cervical cancer. Am J Clin Pathol 2004;122:902-911. (Pubitemid 39577358)
87. Branca M, Giorgi C, Santini D, Di Bonito L, Ciotti M, Benedetto A, Paba P, Costa S, Bonifacio D, Di Bonito P, Accardi L, Favalli C, Syrjänen K. Aberrant expression of vascular endothelial growth factor-C (VEGF-C) is related to grade of cervical intraepithelial neoplasia (CIN) and high-risk Human papillomavirus (HPV), but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer. J Clin Pathol 2006;59:40-47. (Pubitemid 43076237)
88. Branca M, Giorgi C, Santini D, Di Bonito L, Ciotti M, Costa S, Benedetto A, Casolati EA, Favalli C, Paba P, Di Bonito P, Mariani L, Syrjänen S, Bonifacio D, Accardi L, Zanconati F, Syrjänen K. Aberrant expression of a novel inhibitor of apoptosis (Survivin) is related to grade of cervical intraepithelial neoplasia (CIN), but does not predict virus clearance after cone or prognosis in cervical cancer. Am J Clin Pathol. 2005;124:113-121.
89. Branca M, Giorgi C, Ciotti M, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Mariani L, Ruutu M, Favalli C, Syrjänen K. Down-regulation of nucleoside diphosphate (NDP) kinase nm23-H1 expression is unrelated to high-risk Human papillomavirus (HPV) but associated with progression of CIN and unfavourable prognosis of cervical cancer. J. Clin. Pathol. 2006;59:1044-1051.
90. Branca M, Giorgi C, Ciotti M, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Mariani L, Ruutu M, Syrjänen S, Favalli C, Syrjänen K. Over-expression of topoisomerase IIα is related to the grade of cervical intraepithelial neoplasia (CIN) and high-risk Human papillomavirus (HPV), but does not predict prognosis in cervical cancer or HPV clearance after cone treatment. Int J Gynecol Pathol 2006;25:383-392. (Pubitemid 44651772)
91. Branca M, Giorgi C, Ciotti M, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito, P, Paba P, Accardi L, Mariani L, Syrjänen S, Favalli C, Syrjänen K. Relationship of up-regulation of 67-kD laminin receptor to grade of cervical intraepithelial neoplasia and high-risk HPV types and prognosis in cervical cancer. Acta Cytologica 2006;50:6-15. (Pubitemid 43157425)
92. Branca M, Giorgi C, Ciotti M, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Mariani L, Ruutu M, Syrjänen S, Favalli C, Syrjänen K. Upregulation of nuclear factor-κB (NF-κB) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus or disease outcome in cervical cancer. Diagnostic Cytopathol 2006;34:555-563. (Pubitemid 44157177)
93. Branca M, Giorgi C, Ciotti M, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito, P, Paba P, Accardi L, Mariani L, Ruutu M, Syrjänen S, Favalli C, Syrjänen K. Upregulation of telomerase (hTERT) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus (HPV), virus persistence or disease outcome in cervical cancer. Diagnostic Cytopathol 2006; In press.
94. Branca M, Giorgi C, Ciotti M, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito, P, Paba P, Accardi L, Syrjänen S, Favalli C, Syrjänen K. Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN. Anticancer Res 2006;26:1543-1556.
95. Branca M, Giorgi C, Ciotti M, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Syrjänen S, Favalli C, Syrjänen K. Upregulation of proliferating cell nuclear antigen (PCNA) is closely associate with high-risk human papillomavirus (HPV) and progression of cervical intraepithelial neoplasia (CIN), but does not predict disease outcome in cervical cancer. Eur J Gynec & Obstet Reprod Biol 2006; In press.
96. Branca M, Giorgi C, Ciotti M, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito, P, Paba P, Accardi L, Syrjänen S, Favalli C, Syrjänen K. Downregulation of E-cadherin is closely associated with progression of cervical intraepithelial neoplasia (CIN), but not with high-risk human papillomavirus (HPV) or disease outcome in cervical cancer. Eur J Gynaecol Oncol 2006;27:215-223. (Pubitemid 43953413)